BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that Cameron Durrant, chairman and chief executive officer of Humanigen, will present at two healthcare conferences in January 2022. The company and its management are also expected to meet with investors, analysts, bankers and potential partners during the conferences next week. All presentations and meetings will be held virtually. Dr. Durrant will provide updates on recent interactions with regulatory authorities from the United States, United Kingdom and European Union. Dr. Durrant also will provide updates on the enrollment for the ACTIV-5/BET-B clinical trial of lenzilumab in hospitalized COVID-19 patients (NCT04351152), the strategy and potential timing of an amendment to the Emergency Use Authorization (“EUA”) of lenzilumab for COVID-19 to the U.S. Food and Drug Administration (“FDA”) and the timeline for the response to written questions received from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”). Lastly, Dr. Durrant will describe the company’s clinical development pipeline, including foreign COVID-19 trials with lenzilumab and the studies in CAR-T, aGvHD and CMML.
Details of the presentations and link to webcasts are as follows:
Solebury Trout Management Access Event Humanigen is also participating in the Solebury Trout Management Access Event, being held virtually between each of January 10-13 and January 18-20, 2022. Parties interested in 1x1 meetings with management are invited to register for a private meeting at https://troutaccess.com/investor.php/c/SoleburyTrout1x1ManagementAccessEvent2022
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.